Medigene (FSE: MDG1) has extended a deal with fellow German company BioNTech (Nasdaq: BNTX) to advance T cell receptor (TCR) immunotherapies.
The companies started working together in 2022 and will now extend the project beyond the initial three-year term, with the goal of generating novel TCRs directed against multiple newly nominated antigen targets.
Founded in 1994 as a spin-off from the Munich Gene Center, Medigene also has a US office in San Diego, California, and is led by chief executive Selwyn Ho.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze